Debt-to-equity of Outlook Therapeutics, Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Outlook Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Outlook Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -151%, a 0.66% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Outlook Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -151% -0.98% -0.66% 30 Sep 2025
Q2 2025 -145% +17% +11% 30 Jun 2025
Q1 2025 -147% +41% +22% 31 Mar 2025
Q4 2024 -145% +407% +74% 31 Dec 2024
Q3 2024 -150% -3118% -105% 30 Sep 2024
Q2 2024 -162% -706% -130% 30 Jun 2024
Q1 2024 -188% -422% -180% 31 Mar 2024
Q4 2023 -551% -696% -480% 31 Dec 2023
Q3 2023 2968% +2880% +3276% 30 Sep 2023
Q2 2023 543% +454% +505% 30 Jun 2023
Q1 2023 234% +136% +139% 31 Mar 2023
Q4 2022 145% +38% +36% 31 Dec 2022
Q3 2022 88% -224% -72% 30 Sep 2022
Q2 2022 90% -238% -73% 30 Jun 2022
Q1 2022 98% -251% -72% 31 Mar 2022
Q4 2021 107% +646% 31 Dec 2021
Q3 2021 312% +592% 30 Sep 2021
Q2 2021 328% +534% 30 Jun 2021
Q1 2021 349% +527% 31 Mar 2021
Q4 2020 -540% -370% -218% 31 Dec 2020
Q3 2020 -281% -95% -51% 30 Sep 2020
Q2 2020 -206% -23% -13% 30 Jun 2020
Q1 2020 -178% +1% +0.56% 31 Mar 2020
Q4 2019 -170% +2.4% +1.4% 31 Dec 2019
Q3 2019 -185% -11% -6.3% 30 Sep 2019
Q2 2019 -183% -14% -8.2% 30 Jun 2019
Q1 2019 -179% -30% -20% 31 Mar 2019
Q4 2018 -172% -13% -8.2% 31 Dec 2018
Q3 2018 -174% -8.8% -5.3% 30 Sep 2018
Q2 2018 -169% +28% +14% 30 Jun 2018
Q1 2018 -149% +135% +48% 31 Mar 2018
Q4 2017 -159% +77% +33% 31 Dec 2017
Q3 2017 -165% 30 Sep 2017
Q2 2017 -197% 30 Jun 2017
Q1 2017 -284% 31 Mar 2017
Q4 2016 -236% 31 Dec 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.